Delivery of Health Care; Humans; Prevalence; Universities; COVID-19/epidemiology; SARS-CoV-2; Multidisciplinary; Serology
Abstract :
[en] Asymptomatic and pauci-symptomatic cases contribute to underestimating the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Moreover, we have few studies available on the longitudinal follow-up of SARS-CoV-2 antibodies after natural infection. We tested staff members of a Belgian tertiary academic hospital for SARS-CoV-2 IgG, IgM, and IgA antibodies. We analyzed the evolution of IgM and IgG after 6 weeks, and the persistence of IgG after 3 and 10 months. At the first evaluation, 409/3776 (10.8%) participants had a positive SARS-CoV-2 serology. Among initially seropositive participants who completed phases 2 and 3, IgM were still detected after 6 weeks in 53.1% and IgG persisted at 12 weeks in 82.0% (97.5% of those with more than borderline titers). IgG levels were higher and increased over time in symptomatic but were lower and stable in asymptomatic participants. After 10 months, 88.5% of participants had sustained IgG levels (97.0% of those with more than borderline titers).
Disciplines :
Immunology & infectious disease Public health, health care sciences & services
Author, co-author :
HUYNEN, Pascale ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique
GREGOIRE, Céline ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
GOFFLOT, Stéphanie ; Centre Hospitalier Universitaire de Liège - CHU > > Biothèque Hospitalo-Universitaire de Liège (BHUL)
SEIDEL, Laurence ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
MAES, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
VRANKEN, Laura ; Centre Hospitalier Universitaire de Liège - CHU > > Secteur commun NDB
DELCOUR, Sandra ; Centre Hospitalier Universitaire de Liège - CHU > > Secteur commun prélèvements - dispa - labo central Corelab
MOUTSCHEN, Michel ; Centre Hospitalier Universitaire de Liège - CHU > > Service des maladies infectieuses - médecine interne
HAYETTE, Marie-Pierre ; Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique
KOLH, Philippe ; Université de Liège - ULiège > GIGA ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et pathologiques ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
MELIN, Pierrette ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
BEGUIN, Yves ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
✱ These authors have contributed equally to this work.
Language :
English
Title :
Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers.
This study was supported by the Wallonia Region of Belgium (Convention n° 2010075) and the Leon Fredericq Foundation (University of Liège).The ZenTech company kindly provided immunochromatographic assays for IgM and IgG detection on serum samples. The authors thank Michel Georges (VetD, PhD, Director of the GIGA Institute, University of Li?ge) for his support and helpful comments on the study design and the manuscript. We also thank Denis Deriaz (MD, Department of Biostatistics and Medico-economic Information, CHU of Li?ge) for his contribution to the database content before statistical analysis and his comments on the manuscript. The help of Eric Haubruge, Advisor to the Rector of the University of Li?ge, for obtaining the support of the Wallonia Region was really appreciated. We also thank all the persons who have considerably contributed to this study, in particular: Noemi Javaux who organized all the logistical aspects of the study on 5 different sites; Laurent Debra, Michel Raze and Isabelle Simon and their staff who consolidated the IT aspects of this organization; Alain Didderen and his staff who handled appointments with study participants; Ann Robin and her team of more than 15 data managers from the Division of Hematology and other departments of the hospital who managed inclusion of participants in the study; Jocelyne Kariger, Stephanie Leroy and their respective staffs, who verified and encoded all questionnaires; all the nurses involved in collecting blood for the biobanking effort and the serology study; the staff of the Bioth?que Hospitalo-Universitaire de Li?ge (BHUL) and numerous volunteers who handled the biological samples for biobanking and serology; Fran?oise Toussaint, Head Technician of the Laboratory of Infectious Serology and her team, who performed all the serological tests.
Chan, J. F. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 395, 514–523 (2020). DOI: 10.1016/S0140-6736(20)30154-9
Hanson, K. E. et al. Infectious Diseases Society of America Guidelines on the diagnosis of COVID-19: Serologic Testing. Clin. Infect. Dis. 10.1093/cid/ciaa1343 (2020). DOI: 10.1093/cid/ciaa1343
Guo, L. et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin. Infect. Dis. 71, 778–785 (2020). DOI: 10.1093/cid/ciaa310
Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845–848 (2020). DOI: 10.1038/s41591-020-0897-1
Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200–1204 (2020). DOI: 10.1038/s41591-020-0965-6
Steensels, D. et al. Hospital-wide SARS-CoV-2 antibody screening in 3056 staff in a tertiary center in Belgium. JAMA 324, 195–197 (2020). DOI: 10.1001/jama.2020.11160
Pollán, M. et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study. Lancet 396, 535–544 (2020). DOI: 10.1016/S0140-6736(20)31483-5
Carrat, F. et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: A multicohort study. medRxiv. 2020:2020.09.16.20195693.
Moscola, J. et al. Prevalence of SARS-CoV-2 antibodies in health care personnel in the New York City area. JAMA 324, 893–895 (2020). DOI: 10.1001/jama.2020.14765
Garcia-Basteiro, A. L. et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat. Commun. 11, 3500 (2020). DOI: 10.1038/s41467-020-17318-x
Anand, S. et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: A cross-sectional study. Lancet 396, 1335–1344 (2020). DOI: 10.1016/S0140-6736(20)32009-2
Bajema, K. L. et al. Estimated SARS-CoV-2 seroprevalence in the US as of September 2020. JAMA Intern. Med. 181, 450–460 (2021). DOI: 10.1001/jamainternmed.2020.7976
Montesinos, I. et al. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J. Clin. Virol. 128, 104413 (2020). DOI: 10.1016/j.jcv.2020.104413
Tré-Hardy, M. et al. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. Clin. Chem. Lab. Med. 58, 1357–1364 (2020). DOI: 10.1515/cclm-2020-0594
EUA Authorized Serology Test Performance. FDA. https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance 26 July 2020.
Ripperger, T. J. et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity 53, 925–933 (2020). DOI: 10.1016/j.immuni.2020.10.004
Lumley, S. F. et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin. Infect. Dis. 73, e699–e709. 10.1093/cid/ciab004 (2021). DOI: 10.1093/cid/ciab004
Kahre, E. et al. Kinetics and seroprevalence of SARS-CoV-2 antibodies: A comparison of 3 different assays. Sci. Rep. 11, 14893 (2021). DOI: 10.1038/s41598-021-94453-5
Duysburgh, E. et al. Persistence of IgG response to SARS-CoV-2. Lancet Infect. Dis. 21, 163–164 (2021). DOI: 10.1016/S1473-3099(20)30943-9
Roarty, C. et al. Kinetics and seroprevalence of SARS-CoV-2 antibodies in children. Lancet Infect. Dis. 21, e143 (2021). DOI: 10.1016/S1473-3099(20)30884-7
Houlihan, C. F. & Beale, R. The complexities of SARS-CoV-2 serology. Lancet Infect. Dis. 20, 1350–1351 (2020). DOI: 10.1016/S1473-3099(20)30699-X
Lumley, S. F. et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N. Engl. J. Med. 384, 533–540 (2021). DOI: 10.1056/NEJMoa2034545
Harvey, R. A. et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 181, 672–679 (2021). DOI: 10.1001/jamainternmed.2021.0366
Group NS-C-SAE. Performance characteristics of five immunoassays for SARS-CoV-2: A head-to-head benchmark comparison. Lancet Infect. Dis. 20, 1390–1400 (2020). DOI: 10.1016/S1473-3099(20)30634-4
